DermTech, Inc.

DermTech, Inc. is a precision dermatology company that entered the public markets through its business combination with Constellation Alpha Capital Corp., a healthcare-focused blank-check company that traded on Nasdaq under the ticker CNAC. Constellation Alpha Capital Corp. priced its initial public offering in 2017, with Constellation Alpha Capital LLC serving as sponsor. The de-SPAC transaction closed in 2019, bringing DermTech's non-invasive genomic skin cancer testing technology into the public market under the medical technology sector. On May 31, 2022, DermTech filed an 8-K with the Securities and Exchange Commission disclosing a material corporate development as a post-combination operating company. Sign up at SpacDesk for full filing history, sponsor profiles, and deal analytics on this and hundreds of other SPAC transactions.